Cancer prostate, treatment

Template to aid accurate placement of the needles delivering the seeds [Pg.414]

Transperineal brachytherapy is growing in popularity over other treatment options because of a significantly smaller chance of incontinence and impotence, quick treatment and recovery and high success rates [15]. As brachytherapy becomes the method of choice, the procedure must become more reliable. Early detection through accurate biopsy needle placement is crucial to treat prostate cancer. To increase prostate cancer survival rates, it follows that needle placement methods must be improved with MRI guided methods. [Pg.414]

Prostate cancer treatment depends on the stage, age, Gleason score, and PSA concentration. Treatment options include expectant management, radiation therapy, radical prostatectomy, hormonal therapy, and chemotherapy. [Pg.1368]

George DJ. Receptor tyrosine kinases as rational targets for prostate cancer treatment Platelet-derived... [Pg.656]

Flurizan is the (/ (-enantiomer of the well-known NS AID flurbiprofen vide infra) and is currently undergoing Phase 11b clinical trials for prostatic cancer treatment. [Pg.287]

Unlabeled Uses Prevention of bone metastases from breast, prostate cancer, treatment of bone diseases... [Pg.1324]

A reduction in IGF levels could be beneficial in prostate cancer treatment. Administration of the LH-RH antagonist, Cetrorelix, caused a reduction in IGF-I serum levels and tumor IGF-II levels in nude mice transfected with PC-3 cells (LI). Zoladex, a LH-RH agonist with antimitogenic activity, caused a decrease in IGF-I as well as IGFRI levels in DU-145 cells (M9). In the latter case, phosphorylation of IGFRI was prevented, causing a further inhibitory role of IGFRI action. [Pg.135]

American Cancer Society http //www.cancer.org Guidelines for breast and prostate cancer treatment (developed in conjunction with the National Comprehensive Cancer Network (NCCN) recommendations for the early detection of breast, prostate, colon and rectum, and uterine cancers. [Pg.621]

Isolation of the naturally occurring hypothalamic decapeptide hormone luteinizing hormone-releasing hormone or LH-RH has provided another group of effective agents for advanced prostate cancer treatment. The physiologic response to LH-RH depends on both the dose and the mode of administration. Intermittent pulsed LH-RH... [Pg.2424]

Such experimental results, and the observation that LH-RH analogue administration inhibited hormone-dependent prostatic tumour growth in animals [79], directed attention to the potential therapeutic effect of these agonists for the treatment of patients with advanced carcinoma of the prostate and for the clinical management of premenopausal women with cancer of the breast. This exciting advance has provided the clinician with a new initiative in the field of prostatic cancer treatment. [Pg.308]

Moderate to severe vasomotor mptoms associated with menopause, atrophic vaginitis, female hypogonadism, female castration, primary ovarian failure, palliative therapy for breast and prostate cancer, treatment of abnormal uterine bleeding due to hormone imbalance Moderate to severe vasomotor symptoms associated with menopause, atrophic vaginitis, female hypogonadism, female castration, primary ovarian failure Same as conjugated estrogens... [Pg.546]

V. Gimenez, C. James, A. Arminan, R. Schweins, A. Paul, M. Vicent, Demonstrating the importance of polymer-conjugate conformation in solution on its therapeutic output diethylstilbestrol (DES)-polyacetals as prostate cancer treatment, J. Control. Release 159 (2012) 290-301. [Pg.231]

Moreira VM, Salvador JA, Vasaitis TS, Njar VC 2228. (2008) CYP17 inhibitors for prostate cancer treatment—an update. Curr Med Chem 15 868-899... [Pg.763]

The biggest success of pol5mier controlled release systems in cancer therapy however has been in the area of prostate cancer treatment. This therapy is luiique since it uses a hormone-suppressant rather than a chemotherapeutic agent to minimize cancer cell growth in the prostate. Several products include Lupron Depot (TAP Pharmaceuticals), Zoladex (Astra-Zeneca), and Trelstar Depot (Debio RP, Pharmacia). Lupron Depot involves PLA microspheres, Zoladex formulation is an extruded rod, whereas Trelstar depot consists of PLGA microspheres, all of which incorporate LHRH analogues. [Pg.1870]

Cabrespine-Faugeras A, Bayet-Robert M, Bay JO, CholletP, Barthomeuf C (2010) Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutr Cancer 62 148-153... [Pg.2252]

Resveratrol, its structural analogs and novel compounds for prostate cancer treatment... [Pg.138]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...